F or decades, the scientific community has been enlightening us about the complicit role of inflammation in cardiovascular disease (CVD) . What has emerged more recently is that skin inflammation is also associated with vascular inflammation and its cascade of negative health effects.
As dermatologists, we should remain mindful of the fact that where there's smoke, there's fire. Likewise, where there's inflammation on the surface, we need to consider the possibility of underlying disease. Psoriasis has been the steadfast example of inflammatory skin disease, one that has invited a burgeoning amount of research in recent years linking skin inflammation to vascular inflammation. The findings have basically helped piece together the fact that psoriasis is associated with an increased risk of heart attack, stroke, high cholesterol, high blood pressure, and diabetes.
In 2006, Gelfand and colleagues first reported in the Journal of the American Medical Association that psoriasis may be an independent risk factor for heart attack. 1 Later, a 2011 study in the Archives of Dermatology reported that the prevalence of metabolic disease in psoriasis patients was twice that in healthy controls.' Those most at risk for CVD seem to be younger patients with moderate to severe disease, particularly males.' The risks associated with psoriasis also seem to decrease with age, which is an interesting proposition because cardiovascular risk factors generally increase with age.' Although Gelfand and colleagues reported that psoriasis conferred a threefold increased risk of heart attack in young adult patients with severe disease, the findings also showed that their risk remained above normal as they aged. 1 The risk was still 36% higher in a 60-year-old with psoriasis compared to age-matched controls.
The link between skin and systemic inflammation seems obvious, but what is(are) the mechanism(s) by which psoriasis may modify cardiovascular risk? Researchers at the University of Pennsylvania have begun DECKE~t o find some answers. Presenting the results of two new studies at the 2011 American Heart Association Scientific Sessions (Orlando, FL, November 12-16), they reported that psoriasis-related inflammation may potentially increase low-density lipoprotein (LDL) or "bad" cholesterol; it may also compromise the structure and function of high-density lipoprotein (HDL) or "good" cholesterol. 4 ,5 Patients with psoriasis exhibited a 25% reduction in the ability of HDL cholesterol to clear LDL cholesterol from the blood, a function known as HDL efflux capacity. Psoriasis seems to be an independent risk factor for high HDL cholesterol.
Patients with psoriasis also often tend to have other traditional cardiovascular risk factors, such as diabetes, high cholesterol, and obesity." Because of the association with metabolic disease, psoriasis is increasingly becoming redefined as a systemic disease. A question that arises is should dermatologists manage it any differently?
Wang suggested that adalirnumab, a biologic antiinflammatory drug, may not only reduce skin plaques but may also significantly decrease vascular inflammation." The results showed a significant decrease in skin lesion severity in 70% of patients compared to 20% of patients in the control group. The compound also decreased another vascular inflammation marker and risk factor, C-reactive protein, by 51% compared to a 2% decrease among patients in the control group. So treating the skin symptoms may be a viable approach to addressing the systemic effects of psoriasis. Short of having an independent biomarker of increased CVD risk in psoriasis patients or consensus guidelines for the prevention or management of secondary CVD risk in these patients, we have to look to our existing toolbox for interim solutions. In patients with moderate to severe psoriasis and known cardiovascular risk factors, prudence may suggest referral to primary care for a workup and treatment of high cholesterol, diabetes (or prediabetes), hypertension, and obesity. Comanagement may also be necessary for psoriasis patients with no known CVD risk factors if psoriasis independently confers risk.
Meanwhile, doing what we know best-treating psoriasis from a dermatologic perspective-may unwittingly yield heart health benefits too. We recognize that the psychological and physical effects of psoriasis can promote unhealthy lifestyles. Addressing the skin and joint symptoms of psoriasis may encourage patients to reclaim social opportunities, eat better, and exercise more. Moderate weight loss (5 to 10% of body weight) in obese patients, for example, has been proven to improve psoriasis and increase therapeutic response in those with moderate to severe disease."
Although science is still exploring the unhealthy association between psoriasis and CVD and working toward best treatment practices, the emerging evidence gives us pause for thought-that the dermato logic conditions we manage are so often more than skin deep.
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